RxDoctor Payments DataLook up a doctor →

Charles Douchy, MD

Dermatology · Duluth, GANPI 1003808361

Payments from drug & device makers

$19,673in general payments, 2019–2025

Across 999 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • LEO Pharma Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Johnson & Johnson$1K
  • Dermavant Sciences, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $7K from 33 others

What the payments were for

  • Consulting fees$9905%
  • Speaking & faculty fees$5003%
  • Food & beverage$17,51389%
  • Education$6703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,673 in reported general payments places this provider in the 85th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$531,786
Medicare patients
1,634
Services billed
9,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab27$366,262
OtezlaApremilast22$103,083
RinvoqUpadacitinib14$88,441
Dupixent PenDupilumab22$86,896
Taltz AutoinjectorIxekizumab12$81,657
AdbryTralokinumab-Ldrm20$75,333
Dupixent SyringeDupilumab13$45,387
Clobetasol Propionate138$5,317
Ketoconazole216$4,375
Triamcinolone Acetonide349$3,066
Fluorouracil43$2,889
Metronidazole16$2,389
Tacrolimus17$2,317
Clindamycin Phosphate42$1,727
ValacyclovirValacyclovir Hcl55$1,700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,338$366,26227 claims
AmgenOtezla$180$103,08322 claims
AbbVieRinvoq$5,328$88,44114 claims
LEO Pharma Inc.Adbry$2,076$75,33320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 345 dermatology providers in Georgia.

Other dermatology in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →